Vita Golubovskaya

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy.

FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells and .

CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth.

CAR-T Cell Therapy: From the Bench to the Bedside.

GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.

Generation of CAR-T Cells for Cancer Immunotherapy.

Hypoxia Selectively Impairs CAR-T Cells In Vitro.

Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells and .

Major Highlights of the CAR-TCR Summit, Boston, 2016.

DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers.

PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells.

Editorial On "Exosomes, Their Biogenesis and Role in Inter-Cellular Communication, Tumor Microenvironment and Cancer Immunotherapy".

Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma.

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.

Editorial on Special Issue "Immunotherapy, Tumor Microenvironment and Survival Signaling".

CAR-T Cells Targeting Immune Checkpoint Pathway Players.

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth.

Editorial: Novel immunotherapies to treat gastrointestinal solid tumor cancers.

Cancer Immunotherapy: Where Next?

mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth.

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.

Editorial on "Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer".

HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth.